Related references
Note: Only part of the references are listed.Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin - A phase I study for advanced pancreaticobiliary cancer
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Determinants of RASistance to anti-epidermal growth factor receptor agents
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells
T Asano et al.
ONCOGENE (2004)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
H Safran et al.
CANCER INVESTIGATION (2004)
Developing inhibitors of the epidermal growth factor receptor for cancer treatment
V Grünwald et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Epidermal growth factor receptor-targeted therapy for pancreatic cancer
HQ Xiong et al.
SEMINARS IN ONCOLOGY (2002)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
H Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
